Revelation Biosciences, Inc. (REVB)
| Market Cap | 3.98M -16.9% |
| Revenue (ttm) | n/a |
| Net Income | -19.20M |
| EPS | -8.31 |
| Shares Out | 3.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,924 |
| Open | 1.0000 |
| Previous Close | 1.0100 |
| Day's Range | 0.9995 - 1.0000 |
| 52-Week Range | 0.8750 - 11.6000 |
| Beta | -0.14 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About REVB
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the... [Read more]
Financial Performance
Financial StatementsNews
Revelation Biosciences selects Avance Clinical as CRO for Phase 2/3 Titan Study
Revelation Biosciences (REVB) announced that it has selected Avance Clinical, a full-service contract research organization, CRO, with global operations, to serve as the CRO for its Phase 2/3 adaptive...
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat ...
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to...
Revelation Biosciences Quarterly report: Q2 2026
Revelation Biosciences has published its Q2 2026 quarterly earnings report on August 6, 2026.
Revelation Biosciences Earnings release: Q2 2026
Revelation Biosciences released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Revelation Biosciences announces results from market assessment for Gemini
Revelation Biosciences (REVB) announced results of an independent market assessment which identified a potential $94B total addressable market for Gemini, confirming the unmet medical need. “The analy...
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
SAN DIEGO, CA / ACCESS Newswire / August 3, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to...
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to ...
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
SAN DIEGO, CA / ACCESS Newswire / July 10, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to ...
Revelation Biosciences Transcript: Transcript
Gemini, a novel anti-inflammatory therapy, is advancing to a pivotal adaptive phase II/III trial for acute kidney injury, with FDA support for a composite endpoint and efficient study design. Strong clinical and preclinical data support broad potential, and cash runway extends into Q1 2027.
Revelation Biosciences Earnings release
Revelation Biosciences released its earnings on June 12, 2026, summarizing the period's financial results.
Revelation Biosciences Earnings release
Revelation Biosciences released its earnings on June 12, 2026, summarizing the period's financial results.
Revelation Biosciences adds two new members to AKI Advisory Board
Revelation Biosciences (REVB) announced the expansion of its Acute Kidney Injury, AKI, Advisory Board, with the addition of two new members, Dr. Peter Pickkers and Dr. Lui Forni, ahead of…
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to t...
Revelation Biosciences reports FY25 EPS ($14.35) vs ($1,052.16) last year
As of December 31, 2025, Revelation had $10.7 million in cash and cash equivalents, compared to $6.5 million as of December 31, 2024. The increase in cash and cash equivalents…
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to t...
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to tr...
Revelation Biosciences announces formation of AKI advisory board
Revelation Biosciences (REVB) announced formation of an Acute Kidney Injury, AKI, Advisory Board for the upcoming Phase 2/3 AKI clinical trial. This panel brings together internationally recognized Ne...
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to ...
Revelation Gemini data show ‘broad effect,’ says Roth Capital
Roth Capital analyst Jonathan Aschoff says Revelation Biosciences (REVB) showed data from all Phase 1b PRIME trial patients showing that Gemini was similarly effective in reducing inflammatory cytokin...
Revelation Biosciences presents additional data from Prime Clinical Study
Revelation Biosciences (REVB) presented additional positive data analysis from the PRIME Study at the International Conference on Advances in Critical Care Nephrology in San Diego. Presented data demo...
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
- A majority of CKD patients present with cellular inflammation and immunoparalysis predose - -Gemini durably normalizes cellular inflammation and restores immunocompetence - SAN DIEGO, CA / ACCESS Ne...
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammatio...
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammatio...
Revelation Biosciences Slides: Corporate presentation
Revelation Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on March 1, 2026.